Premium
Use of the IL‐6R antagonist tocilizumab in hospitalized COVID‐19 patients
Author(s) -
Patel K.,
Gooley T. A.,
Bailey N.,
Bailey M.,
Hegerova L.,
Batchelder A.,
Holdread H.,
Dunleavy V.,
Downey T.,
Frisvold J.,
Megrath S.,
Pagarigan K.,
Szeto J.,
Rueda J.,
Islam A.,
Maree C.,
Nyatsatsang S.,
Bork S. E.,
Lipke A.,
O’Mahony D. S.,
Wagner T.,
Pulido J.,
Mig J.,
Youssef S.,
Hartman M.,
Goldman J. D.,
Pagel J. M.
Publication year - 2021
Publication title -
journal of internal medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.625
H-Index - 160
eISSN - 1365-2796
pISSN - 0954-6820
DOI - 10.1111/joim.13163
Subject(s) - tocilizumab , medicine , context (archaeology) , cytokine release syndrome , retrospective cohort study , prospective cohort study , intensive care unit , clinical trial , medical record , cohort , cohort study , covid-19 , disease , paleontology , infectious disease (medical specialty) , biology
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom